iBio, Inc. (NYSE:IBIO) shares are trading higher after the company provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection.
"Combined with data from previous immune-response studies, these pathology results help demonstrate the potential value of LicKM as a useful tool in our vaccine development toolbox," said Tom Isett, Chairman and CEO of iBio.
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators.
iBio's stock was trading 21.7% higher at $1.68 at the time of publication. The stock has a 52-week high of $7.45 and a 52-week low of $0.96.